文献速递关节外科

接受初次全关节置换术的重度肥胖患者使用直接口服抗凝药与阿司匹林相比可能经历更高的静脉血栓栓塞发生率

Morbidly Obese Patients Undergoing Primary Total Joint Arthroplasty May Experience Higher Rates of Venous Thromboembolism When Prescribed Direct Oral Anticoagulants vs Aspirin.
PubMed 文献 · J Arthroplasty · 2022-02-05

这项回顾性研究分析了897例体重指数>40 kg/m2接受初次单侧全关节置换术的患者,评估术后静脉血栓栓塞与预防性药物之间的关联。多因素logistic回归显示,与单用阿司匹林相比,单用直接口服抗凝药(具体为阿哌沙班)与静脉血栓栓塞风险升高相关(比值比2.962,P=0.016)。无论使用何种预防药物,接受全膝关节置换术的患者发生静脉血栓栓塞的比值至少是全髋关节置换术患者的4.5倍(OR 4.830,P=0.019)。

要点

  • BMI>40 kg/m2患者单用阿哌沙班预防VTE与单用阿司匹林相比,VTE风险升高(OR 2.962,P=0.016)。
  • BMI>40 kg/m2患者接受全膝关节置换术较全髋关节置换术的VTE风险至少升高4.5倍(OR 4.830,P=0.019)。
  • 当前指南因证据质量低而不推荐BMI>40 kg/m2患者使用直接口服抗凝药。

核心结论

  • 在BMI>40 kg/m2患者的大型回顾性样本中,全关节置换术后使用直接口服抗凝药(具体为阿哌沙班)预防VTE与单用阿司匹林相比,VTE并发症的比值升高。

研究设计与样本

  • 回顾性研究,分析897例BMI>40 kg/m2接受初次单侧全关节置换术的患者,收集人口学和合并症变量,采用多因素logistic回归评估术后VTE与预防性药物之间的关联。

主要发现

  • 控制合并症后,单用直接口服抗凝药(具体为阿哌沙班)预防VTE与单用阿司匹林相比,BMI>40 kg/m2患者发生VTE的风险升高(比值比2.962,P=0.016)。
  • 无论VTE预防药物如何,BMI>40 kg/m2患者接受全膝关节置换术较全髋关节置换术发生VTE的比值至少升高4.5倍(OR 4.830,P=0.019)。

关键数值与推荐

  • 当前指南因证据质量低而不推荐BMI>40 kg/m2患者使用直接口服抗凝药。
  • 单用直接口服抗凝药(具体为阿哌沙班)与单用阿司匹林相比,VTE的比值比为2.962(P=0.016)。
  • 全膝关节置换术与全髋关节置换术相比,VTE的比值比为4.830(P=0.019)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Morbidly obese (body mass index [BMI] >40 kg/m2) patients undergoing total joint arthroplasty (TJA) are at high risk for postoperative venous thromboembolism (VTE); however, there is debate surrounding the optimal pharmacologic agent for prevention of VTE after TJA in this patient subset. Current guidelines recommend against direct-acting oral anticoagulants (DOACs) in patients of BMI >40 kg/m2 due to low quality evidence justifying their use. We evaluated whether patients of BMI >40 kg/m2 undergoing primary unilateral TJA would have increased risk of postoperative VTE if prescribed DOACs compared to non-DOAC agents such as aspirin. METHODS: This retrospective study analyzed 897 patients of BMI >40 kg/m2 undergoing primary unilateral TJA. Demographic and comorbidity-related variables were collected. The association between postoperative VTE and prophylactic pharmacologic agent prescribed was evaluated by multivariate logistic regression. RESULTS: After controlling for comorbidities, we found that the sole use of DOACs, specifically apixaban, for VTE prophylaxis was associated with an increased risk of developing VTE compared to prophylaxis with aspirin alone in patients of BMI >40 kg/m2 (odds ratio 2.962, P = .016). Regardless of VTE prophylactic agent, patients with BMI >40 kg/m2 undergoing TKA had at least 4.5-fold increased odds of developing VTE compared to patients undergoing THA (OR 4.830, P = .019). CONCLUSION: In our retrospective study of a large sample size of patients with BMI >40 kg/m2, we found that the use of DOACs, specifically apixaban, for VTE prophylaxis following TJA was associated with increased odds of a VTE complication compared to the use of aspirin alone.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Humphrey TJ, O'Brien TD, Melnic CM, et al. Morbidly Obese Patients Undergoing Primary Total Joint Arthroplasty May Experience Higher Rates of Venous Thromboembolism When Prescribed Direct Oral Anticoagulants vs Aspirin. J Arthroplasty. 2022. PMID: 35131389. doi:10.1016/j.arth.2022.01.089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。